Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Working Capital to Current Liabilities Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: 6.31%

Cyteir Therapeutics Inc Working Capital to Current Liabilities Ratio 2 year CAGR is 6.31% for the Trailing 12 Months (TTM) ending September 30, 2023. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Cyteir Therapeutics Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 22.12, a 19.70% change year over year.
  • Cyteir Therapeutics Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 18.48.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email